Cargando…
Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial
BACKGROUND: Evidence increasingly points to the importance of chronic hypoxia in the tubulointerstitium as a final common pathway to end-stage renal disease (ESRD). Beraprost sodium (BPS) is an orally active prostacyclin (PGI(2)) analogue demonstrating prevention of the progression of chronic kidney...
Autores principales: | Koyama, Akio, Fujita, Toshiro, Gejyo, Fumitake, Origasa, Hideki, Isono, Masanao, Kurumatani, Hajimu, Okada, Kiyonobu, Kanoh, Hiroyuki, Kiriyama, Takashi, Yamada, Shunsuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608181/ https://www.ncbi.nlm.nih.gov/pubmed/26475266 http://dx.doi.org/10.1186/s12882-015-0130-5 |
Ejemplares similares
-
A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design
por: Nakamoto, Hidetomo, et al.
Publicado: (2014) -
Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study
por: Kurumatani, Hajimu, et al.
Publicado: (2021) -
The Prostacyclin Analog Beraprost Sodium Ameliorates Characteristics of Metabolic Syndrome in Obese Zucker (Fatty) Rats
por: Sato, Nahoko, et al.
Publicado: (2010) -
Prostacyclin Analogue Beraprost Inhibits Cardiac Fibroblast Proliferation Depending on Prostacyclin Receptor Activation through a TGF β-Smad Signal Pathway
por: Chen, Yun, et al.
Publicado: (2014) -
A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
por: Takenaka, M., et al.
Publicado: (2017)